scholarly journals Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases

Oncotarget ◽  
2017 ◽  
Vol 8 (45) ◽  
pp. 79785-79792 ◽  
Author(s):  
Lianyuan Tao ◽  
Dianrong Xiu ◽  
Abuduhaibaier Sadula ◽  
Chen Ye ◽  
Qing Chen ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumor ◽  
Surgical Resection ◽  
Primary Tumor ◽  
Pancreatic Neuroendocrine Tumor

Growth factor signaling in pancreatic neuroendocrine tumor metastases.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 256-256
Author(s):  
Brenna Rheinheimer ◽  
Ronald Heimark ◽  
Tun Jie
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumor ◽  
Signaling Pathways ◽  
Surgical Resection ◽  
Metastatic Disease ◽  
Genetic Variants ◽  
Genomic Analysis ◽  
Pancreatic Neuroendocrine Tumor ◽  
Proliferation Index ◽  
Who Grade

256 Background: Pancreatic neuroendocrine tumors (PanNETs) are among one of the fastest growing cancer diagnoses, yet clinical management for patients with metastatic disease is largely empirically based. Currently, surgical resection remains the only curative option; however, surgical resection of metastatic disease may not be feasible. Preliminary genomic analysis of primary PanNETs revealed a complex mutational landscape with four common oncogenic events; but, critical activation pathways of metastatic lesions have yet to be elucidated. Therefore, pan-genomic analysis of metastatic PanNETs is necessary to understand which genes/pathways are deregulated in PanNET metastases for potential therapeutic exploitation. Methods: We initiated a preliminary genomic sequencing study to evaluate mutations in a set of matched primary and metastatic PanNETs to determine genetic variants involved in metastasis to the liver. De-identified FFPE tumor samples were analyzed from patients who underwent surgical resection without receiving preoperative therapy. DNA was isolated and whole exome sequencing was performed using the Nextera Rapid Capture Exome Kit by Illumina on an Illumina HiSeq 2000/2500. The following criteria were used to define genetic variants: bidirectional, non-synonymous, clean mapping in IGV, ≥ 15X coverage, and an alternate allele frequency of 0.3 ≤ x ≤ 0.7. Results: All metastatic PanNETs were classified as WHO grade G2/G3 based on their KI-67 proliferation index. Each primary PanNET contained an average of 102 genetic variants while liver metastases showed an average of 124 genetic variants. MUFFINN and string analysis revealed that primary PanNETs contained enrichment for mutations involved in the PI3K/Akt and Ras signaling pathways while liver metastases showed enrichment for mutations involved in the MAPK and ErbB signaling pathways. Additionally, two-thirds of liver metastases contained somatic mutations in FGFR3. Conclusions: We have discovered novel pathways that have the potential to regulate pancreatic neuroendocrine tumor metastasis along with an innovative signaling pathway that may sustain metastatic growth and survival as well as exploitation for therapeutic potential.

Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review

2009 ◽  
Vol 197 (3) ◽  
pp. 376-381 ◽  
Author(s):  
Matias Bruzoni ◽  
Purvi Parikh ◽  
Rolando Celis ◽  
Chandrakanth Are ◽  
Quan P. Ly ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Primary Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Single Institution

Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor

2018 ◽  
Vol 155 (6) ◽  
pp. 483-492
Author(s):  
S. Deguelte ◽  
L. de Mestier ◽  
O. Hentic ◽  
J. Cros ◽  
R. Lebtahi ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Primary Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Surgery

scholarly journals A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor

2017 ◽  
Vol 3 (1) ◽  
Author(s):  
Asahi Sato ◽  
Toshihiko Masui ◽  
Nao Sankoda ◽  
Kenzo Nakano ◽  
Yuichiro Uchida ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Surgical Resection ◽  
Pancreatic Neuroendocrine Tumor

Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15693-e15693
Author(s):  
Walid Labib Shaib ◽  
Mckenna Penely ◽  
Katerina Mary Zakka ◽  
Renjian Jiang ◽  
Mehmet Akce ◽  
...  
Keyword(s):  
Small Intestine ◽  
Neuroendocrine Tumor ◽  
Surgical Resection ◽  
Primary Tumor ◽  
Surgical Margin ◽  
Stage Iv ◽  
Patient Characteristics ◽  
Cox Proportional Hazards ◽  
Female Ratio ◽  
Survival Difference

e15693 Background: Resection of the primary tumor in metastatic neuroendocrine tumor (NET) is controversial. The aim of this study is to evaluate survival outcomes and identify prognostic variables of surgical resection of the primary tumor in metastatic NET patients. Methods: Data were obtained from all US hospitals that contributed to the National Cancer Database (NCDB) between 2004 and 2013. Chi-square and ANOVA tests were done to identify factors associated with surgical modality. Univariate and multivariate cox proportional hazards models were used for association between patient characteristics and survival. Kaplan-Meier curves were generated and log-rank tests conducted to compare the survival difference of patient characteristics. Results: A total of 2,361 patients between 18 and 90 years of age with stage IV well/intermediate-differentiated NET were identified. The mean age was 62.1 years (SD±13), with an equal male to female ratio (50.0%). Majority of NET primaries were in the small intestine (33.0%), pancreas (26.3%), and lung (24.4%). The majority were well differentiated tumors (69.6%) and 42.5% of patients underwent surgery at the primary site. On multivariate analysis total surgical resection of the primary (HR 0.44; 0.22-0.90; p < 0.001), female sex, year of diagnosis 2010-2014, negative surgical margin, Charlson-Deyo score < 2, and age < 51 years at diagnosis were associated with better overall survival (OS). Conclusions: Resection of the primary in stage IV well/intermediate-differentiated NET was associated with improved 5-year OS compared to patients with no surgery in small intestine (60.1% vs 44.2%), lung (70.0% vs 20.2%), and pancreas tumors (59.3% vs 30.6%).

Sign in / Sign up

Export Citation Format

Share Document